Literature DB >> 12645041

Acute administration of the selective D3 receptor antagonist SB-277011A blocks the acquisition and expression of the conditioned place preference response to heroin in male rats.

Charles R Ashby1, Mousumi Paul, Eliot L Gardner, Christian A Heidbreder, Jim J Hagan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12645041     DOI： 10.1002/syn.10188

Source DB:  PubMed          Journal:  Synapse        ISSN： 0887-4476            Impact factor:   2.562


× No keyword cloud information.
  36 in total

1.  The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.

Authors:  Arlene C Pak; Charles R Ashby; Christian A Heidbreder; Maria Pilla; Jeremy Gilbert; Zheng-Xiong Xi; Eliot L Gardner
Journal:  Int J Neuropsychopharmacol       Date:  2006-08-31       Impact factor: 5.176

Review 2.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

Review 3.  Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D(3) receptor.

Authors:  R J Beninger; T J Banasikowski
Journal:  Neurotox Res       Date:  2008-08       Impact factor: 3.911

4.  Dopamine D3 Receptor Antagonist (GSK598809) Potentiates the Hypertensive Effects of Cocaine in Conscious, Freely-Moving Dogs.

Authors:  Nathan M Appel; Shou-Hua Li; Tyson H Holmes; Jane B Acri
Journal:  J Pharmacol Exp Ther       Date:  2015-07-15       Impact factor: 4.030

5.  Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat.

Authors:  Jeremiah W Bertz; Jianyong Chen; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2014-07-03       Impact factor: 4.530

Review 6.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

Review 7.  Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction.

Authors:  Bernard Le Foll; Patricia Di Ciano
Journal:  Eur Neuropsychopharmacol       Date:  2014-09-16       Impact factor: 4.600

8.  The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents.

Authors:  Chloe J Jordan; Bree Humburg; Myra Rice; Guo-Hua Bi; Zhi-Bing You; Anver Basha Shaik; Jianjing Cao; Alessandro Bonifazi; Alexandra Gadiano; Rana Rais; Barbara Slusher; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2019-04-08       Impact factor: 5.250

9.  Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.

Authors:  Zheng-Xiong Xi; Jeremy Gilbert; Arlene C Campos; Nicole Kline; Charles R Ashby; Jim J Hagan; Christian A Heidbreder; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 10.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.